Orforglipron (Foundayo) introduces a new oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken without food ...

The data shows that the drugs triggered activity in the central amygdala that reduced dopamine release into the brain's reward circuitry.

Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly’s LLY0.66%increase; green up pointing triangle Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company ...

Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. Indianapolis-based Lilly will celebrate 150 ...

The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as “triple-G,” injectable retatrutide levies a triple whammy on the GLP-1, GIP and ...

Eli Lilly opposes the White House's push to codify 'most favored nation' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...

Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: obesity. Now, the drugmaker is taking on another significant public health predicament: sleep ...

Eli Lilly and Co. anticipates shipping newly approved Foundayo (orforglipron) within the next week, as the drug becomes the second oral weight-loss glucagon-like peptide-1 (GLP-1) receptor agonist to ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

Matthew Herper covers medical innovation — both its promise and its perils. Everything changed with a white envelope. On Dec. 20, 2018, Jacob Van Naarden, the chief operating officer of a biotech ...